Use access key #2 to skip to page content.
$5.81 -0.36 (-5.83%)
1/9/2009 4:00 PM

Enzon Pharmaceuticals, Inc. (ENZN)

CAPS Rating:
****

A biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and adjacent diseases.

View All Commentary (ENZN)

Recs

0

Avatar pjani06 (93.66) Submitted: 7/26/08 12:33 PM : Outperform Start Price: $7.50 ENZN Score: 5.74

Our demographic picture as well as increased attention to prolonged life will allow this company to easily hit revenues beyond 400 million at the very least within next 5 years. apply a simple 20% oper margin, less potential future debt exp of $40 mil, and you have at least $40 mill left over in net income. multiply that by 10 for a high growth biotech/pharma and this company should be worth atleast $400mill today

Report this Post Replies: 0 | Reply | Permalink

Featured Broker Partners

Sponsored Links